55 results
DFAN14A
NVS
Novartis AG
10 Jul 23
Additional proxy materials by non-management
4:08pm
,” “opportunity,” “to address,” “commitment,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications
DEFM14A
KDNY
Chinook Therapeutics Inc
10 Jul 23
Proxy related to merger
4:01pm
that is still in effect (any such law or a judgment, a “legal restraint”);
(i) the waiting period under the HSR Act, and any commitment by the parties hereto … is a party that obligates the Company or such Company Subsidiary to make any expenditure, including a capital commitment, loan or capital expenditure
PREM14A
KDNY
Chinook Therapeutics Inc
27 Jun 23
Preliminary proxy related to merger
4:02pm
”);
(i) the waiting period under the HSR Act, and any commitment by the parties hereto not to consummate the Merger and the other transactions … that obligates the Company or such Company Subsidiary to make any expenditure, including a capital commitment, loan or capital expenditure, in an aggregate
DEFA14A
KDNY
Chinook Therapeutics Inc
12 Jun 23
Additional proxy soliciting materials
4:06pm
this news comes as a surprise to many of you. As it sinks in and the details are explained, I hope you will feel proud that our commitment, expertise
DFAN14A
dcy0w
12 Jun 23
Additional proxy materials by non-management
9:41am
DEFA14A
ituq4o8 ar
12 Jun 23
Additional proxy soliciting materials
7:05am
8-K
EX-2.1
klz nu2xbryhyhkvn
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
PRE 14A
ff2qx
17 Apr 23
Preliminary proxy
4:51pm
424B5
heh n2t4op
10 Nov 22
Prospectus supplement for primary offering
4:59pm
S-8
EX-99.1
2jz kj07l8
10 Nov 22
Registration of securities for employees
4:00pm
424B5
wlyf2w wv8zft
25 May 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-5.1
pu030 2imh
25 May 22
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
4:09pm
424B5
zp7b6o
24 May 22
Prospectus supplement for primary offering
4:26pm
S-3ASR
6eujimug sz3u
24 May 22
Automatic shelf registration
4:01pm
8-K
EX-99.1
x833b04k61j5
30 Nov 21
Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China
4:04pm
8-K
EX-5.1
4ib u4tl94p4ogei
10 Nov 21
Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering
5:24pm
424B5
rlm1 a3y7chj1otci9y
10 Nov 21
Prospectus supplement for primary offering
5:22pm